CTOs on the Move


 
XIFIN, Inc. is an innovative software and services company dedicated to optimizing the economics of healthcare. The company`s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xifin.com
  • 12225 El Camino Real
    San Diego, CA USA 92130
  • Phone: 858.793.5700

Executives

Name Title Contact Details
John Kelly
Chief Information Officer Profile

Similar Companies

Dynacq Healthcare

Dynacq Healthcare, Inc. is a holding company that through its subsidiaries develops and manages acute care hospitals that principally provide specialized surgeries. The Company operates primarily in the United States and China. The Company focuses on

Ranfac

Ranfac provides contracted certified sterilization validation services that meet current requirements for each form of sterilization. We can provide turnkey product validation with all necessary documentation, product sample submissions and quarterly

PRONERVE

PRONERVE is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

The Association of Dental Technologist of Ontario

The Association of Dental Technologist of Ontario is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.